Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martha Skup

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Gastroenterology|September 27, 2013
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitisBrian G Feagan, William J Sandborn, Andreas Lazar, et al.
Journal of Gastroenterology|March 22, 2017
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.
European Journal of Gastroenterology & Hepatology|December 8, 2016
The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot studyWelmoed K van Deen, Arlen Spiro, A Burak Ozbay, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADASimon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Gastroenterology|September 27, 2013
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitisBrian G Feagan, William J Sandborn, Andreas Lazar, et al.
Journal of Gastroenterology|March 22, 2017
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.
European Journal of Gastroenterology & Hepatology|December 8, 2016
The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot studyWelmoed K van Deen, Arlen Spiro, A Burak Ozbay, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADASimon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Pageof 5